CLINICAL_TRIALS
trial_result
· 2021-08-27
Clinical Trial Update: Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma [Phase 2]
Summary
Phase 2 trial update investigating Orelabrutinib in combination with R2 regimen for relapsed/refractory CD20+ B-cell lymphoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Puyang Oilfield General Hospital | Conditions: B-cell Lymphoma | Phase 2 | Status: UNKNOWN